Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of its antibiotic immunotherapy, CD201, for the treatment of life-threatening multi-drug resistant (MDR) Gram-negative bacterial infections. CD201 is the first development candidate to be generated by Cidara’s novel Cloudbreak™ immunotherapy discovery platform, designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
CD201 is a first-in-class, bispecific antibiotic immunotherapy being developed for the treatment of multi-drug resistant bacterial infections, including those caused by MCR-1-producing pathogens. CD201 works by binding to a target present on a wide range of Gram-negative bacteria, including MCR-1-positive strains, while simultaneously recruiting immune components to an infection site to coordinate localized host-mediated infection clearance. CD201 has demonstrated potent antibacterial activity in vitro against a number of clinically significant Gram-negative bacteria, including Klebsiella, Acinetob
CARB-X is the world’s largest public-private partnership focused on antibacterials, created by the U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). CARB-X is funded by BARDA and the London-based Wellcome Trust, a global charitable foundation, and administered by the Boston University School of Law.
WATCH: Cloudbreak™ Overview Video
“This grant from CARB-X validates the progress we’ve made to date with our Cloudbreak platform,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We believe that the Cloudbreak immunotherapy approach has the potential to transform the way infectious diseases are treated, similar to the way immunotherapy has transformed cancer treatment. With this valuable support from CARB-X, we look forward to accelerating the development of CD201 through the critical early stages, including continuing our IND-enabling studies.”